Sermorelin for Post-COVID and Long-COVID Recovery: A Women's Protocol

What Is Sermorelin and Why Are Clinicians Considering It for Long-COVID?

Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates the pulsatile secretion of endogenous growth hormone (GH), which then drives hepatic production of insulin-like growth factor 1 (IGF-1). Unlike exogenous recombinant GH, sermorelin keeps your own pituitary in the loop, so GH release remains subject to normal feedback controls.

Long-COVID affects an estimated 10-30% of people infected with SARS-CoV-2, with fatigue, post-exertional malaise, brain fog, and dysautonomia among the most disabling symptoms. Researchers have identified mitochondrial dysfunction, persistent immune activation, and disrupted neuroendocrine signaling as core mechanisms, and all three overlap with domains where GH and IGF-1 are physiologically active.

GH regulates mitochondrial biogenesis, protein synthesis, immune cell maturation, and cognitive function. When GH secretion is suppressed, as it can be after acute viral illness and during chronic inflammatory states, the downstream consequences map closely onto the long-COVID symptom cluster. That mechanistic overlap is the rationale for using sermorelin here. The rationale is plausible. The direct evidence is thin, and you deserve to know that clearly from the start.

Why Women's Biology Matters Specifically Here

Women make up a disproportionate share of long-COVID patients. A 2023 analysis in JAMA Network Open found women 60% more likely than men to develop long-COVID symptoms lasting more than 28 days. Sex hormones modify GH secretion meaningfully: estradiol amplifies GH pulse amplitude, while progesterone modulates GH receptor sensitivity. This means a perimenopausal woman with declining estradiol may already be starting from a lower GH-secretion baseline before SARS-CoV-2 further suppresses it.

Women with PCOS have blunted GH pulsatility independent of infection. Women in the postpartum period have unique neuroendocrine vulnerability. These distinctions matter for dosing and for interpreting labs, and they are discussed in each section below.

The Mechanistic Case: What Sermorelin May Address in Long-COVID

The core pathophysiology of long-COVID includes at least four targets where GH/IGF-1 signaling is directly relevant.

Mitochondrial Dysfunction

Skeletal muscle biopsies from long-COVID patients show reduced mitochondrial complex I activity and lower ATP production capacity. GH stimulates PGC-1alpha expression, a master regulator of mitochondrial biogenesis. IGF-1 drives mitochondrial fusion and reduces reactive oxygen species in skeletal and cardiac muscle. The connection is mechanistic, not yet proven in a sermorelin-specific long-COVID trial, but it provides a biological reason to expect benefit.

Immune Dysregulation

Long-COVID is associated with persistently elevated inflammatory cytokines including IL-6, TNF-alpha, and interferons. GH receptors are expressed on T-cells, B-cells, and natural killer cells. In GH-deficient adults, IGF-1 replacement has been shown to restore NK-cell cytotoxicity and improve CD4/CD8 ratios. Sermorelin raises IGF-1 to physiologic, not supraphysiologic, levels, which may reduce immune senescence without suppressing adaptive immunity.

Cognitive Function and Neuroinflammation

Brain fog in long-COVID maps to prefrontal and hippocampal dysfunction. IGF-1 crosses the blood-brain barrier and acts as a neurotrophic factor, supporting synaptic plasticity and myelin maintenance. A 2012 Journal of Clinical Endocrinology and Metabolism study found that GH-deficient adults treated with GHRH analogs showed improved memory consolidation and reduced hippocampal atrophy rates.

Sleep Architecture

Non-restorative sleep is near-universal in long-COVID. GH is secreted predominantly during slow-wave sleep (SWS), and SWS is disrupted by COVID-associated neuroinflammation. Bedtime sermorelin dosing may restore the GH-SWS coupling, improving sleep quality and in turn GH secretion. This is a feedback loop, not a single-direction effect.

The Evidence: What We Know, What We Don't, and What Is Extrapolated

This is the section most articles skip. You should read it carefully.

Level 1 Evidence (RCTs): Does Not Yet Exist for Long-COVID

No randomized controlled trial has enrolled long-COVID patients and tested sermorelin as an intervention. Any clinician or website claiming RCT-level evidence for this specific use case is overstating the data.

Level 2 Evidence: GH Deficiency and Fatigue Trials

The KIMS study (Pfizer International Metabolic Database), a large multinational observational database of GH-deficient adults, showed consistent improvements in fatigue scores, quality of life, and body composition with GH restoration over 2-4 years. These patients were not post-COVID, but their symptom profile resembles it closely enough to generate a reasonable hypothesis.

A smaller 2019 randomized trial published in Clinical Endocrinology tested a GHRH analog (tesamorelin, structurally related to sermorelin) in HIV-associated neurocognitive disorder and found significant improvement in executive function at 24 weeks in women participants.

Level 3 Evidence: Observational and Practitioner Reports

Integrative medicine and functional medicine clinicians have published case series and retrospective analyses describing improvements in long-COVID fatigue and cognition with sermorelin. These are not placebo-controlled and carry a high risk of regression to the mean. They are useful for generating hypotheses and dosing frameworks, not for establishing efficacy.

The Evidence Gap for Women

Women were underrepresented in the foundational GH-secretagogue trials. The KIMS database included approximately 40% women, but sex-stratified outcomes were not consistently reported in early publications. IGF-1 reference ranges differ by sex and shift across the menstrual cycle. This makes interpreting your lab values during sermorelin treatment more complex than a single-number target suggests.

The Protocol: Dose, Route, Frequency, and Cycle Length

The following framework synthesizes published GHRH-analog dosing studies, the American Association of Clinical Endocrinology (AACE) adult GH deficiency guidelines, and clinical practice patterns reported in observational literature. It is not a substitute for individualized medical supervision.

Starting Dose by Life Stage

Reproductive years (roughly ages 18-40): Start at 200 mcg subcutaneously at bedtime. GH pulsatility is highest in this life stage, so lower starting doses reduce the risk of overshooting IGF-1 into supraphysiologic range.

Perimenopause (roughly ages 40-55, variable): Estradiol decline blunts GH pulse amplitude, so IGF-1 baseline is often lower. Start at 200 mcg, but expect to titrate to 250-300 mcg by week 6 if IGF-1 remains in the lower quartile of the age-adjusted reference range.

Post-menopause (no menstrual cycles for 12+ months): GH secretion declines by approximately 14% per decade after age 30, and the decline accelerates post-menopausally without estrogen. AACE guidelines suggest starting GH-stimulating therapy at lower doses and titrating more slowly in older adults. Start at 150-200 mcg. Women on menopausal hormone therapy (MHT) containing oral estradiol may need higher sermorelin doses because oral estrogen increases GH clearance via first-pass hepatic metabolism. Transdermal estradiol does not carry this interaction to the same degree.

Postpartum (not breastfeeding, cleared for peptide therapy): Postpartum GH regulation is complex. Prolactin competes with GH at shared receptor subtypes. Sermorelin is not recommended until at least 3 months postpartum, breastfeeding has ended, and prolactin has normalized. See the pregnancy and lactation section below.

Route and Timing

Subcutaneous injection, typically into the abdomen or thigh, administered 30 minutes before sleep. Bedtime dosing aligns with the natural circadian GH surge and may amplify SWS-coupled GH release. Avoid dosing within 2 hours of a high-carbohydrate meal because acute insulin release blunts GH secretion.

Frequency

Daily dosing 5-6 nights per week is the most commonly used schedule in observational literature. Some practitioners use 5 days on, 2 days off to reduce theoretical pituitary desensitization, though evidence for this concern with sermorelin specifically is limited.

Cycle Length

Minimum meaningful trial: 12 weeks. Most benefits in the GH-deficiency literature emerged over 6-12 months of sustained therapy. A reasonable long-COVID protocol is:

• Weeks 1-6: 200 mcg nightly, check IGF-1 at week 6
• Weeks 7-12: adjust dose based on IGF-1 and symptom trajectory
• Week 12: formal reassessment, decision to continue or pause
• Month 6: consider a 4-week off-cycle to reassess baseline IGF-1

Monitoring Labs: What to Check and When

Skipping labs is not optional in this protocol. Sermorelin is physiologically active, and unsupervised use without monitoring can drive IGF-1 into ranges associated with insulin resistance or fluid retention.

Baseline Labs Before Starting

| Lab | Why It Matters for Women | |-----|--------------------------| | IGF-1 (age- and sex-adjusted) | Your starting point; guides dose selection | | Fasting glucose and insulin | GH can raise fasting glucose transiently | | HbA1c | Rules out undiagnosed insulin resistance common in PCOS | | Thyroid panel (TSH, free T4) | Hypothyroidism blunts GH response; common in women with long-COVID or postpartum history | | Cortisol (AM, fasting) | HPA axis suppression alters GH secretion | | Prolactin | Elevated prolactin inhibits GH receptor signaling | | CBC with differential | Baseline immune status | | CMP | Liver and kidney function affect peptide clearance | | Estradiol and FSH (if perimenopausal or postmenopausal) | Contextualizes IGF-1 interpretation | | LH, testosterone (if PCOS suspected) | PCOS alters GH pulsatility |

Follow-Up Labs

Check IGF-1, fasting glucose, and a symptom-specific panel at weeks 6 and 12. If IGF-1 rises above the age-adjusted upper quartile, reduce the dose. If fasting glucose rises more than 10 mg/dL from baseline, pause and reassess.

The AACE Growth Hormone Deficiency Clinical Practice Guidelines target IGF-1 in the middle tertile of the age- and sex-specific reference range, roughly the 50th-75th percentile, not the ceiling.

Expected Timeline of Outcomes

Symptom response is not immediate. Here is what observational and GH-deficiency data suggest:

• Weeks 2-4: Improved sleep depth reported by a majority of patients in GH-secretagogue studies; this is often the first change noticed.
• Weeks 6-8: Energy levels and exercise tolerance begin to improve. A 2020 systematic review in Growth Hormone and IGF Research found that fatigue scores improved significantly by 8 weeks in GH-deficient adults treated with GHRH analogs.
• Weeks 12-16: Cognitive improvements in attention and working memory, based on the tesamorelin/HAND data cited earlier.
• Months 4-6: Body composition changes (reduced visceral fat, modest lean mass gain), relevant for long-COVID patients who have experienced deconditioning.

Not every woman will respond. Approximately 20-30% of long-COVID patients may have ongoing viral reservoirs or autoimmune mechanisms that sermorelin does not address. If you see no change in fatigue or IGF-1 after 12 weeks of correctly dosed therapy, continuing indefinitely is not supported by evidence.

Pregnancy, Lactation, and Contraception: Required Reading

Sermorelin is contraindicated in pregnancy. There are no adequate human data on fetal safety, and animal studies suggest GHRH analogs may alter placental GH signaling, which is critical to normal fetal growth. The FDA has not assigned a formal pregnancy category to sermorelin as a compounded peptide, but the absence of safety data is itself a contraindication. Do not attempt pregnancy while using sermorelin.

If you are in your reproductive years and sexually active, use a reliable contraceptive method throughout the treatment cycle. Sermorelin should be stopped at least 4-6 weeks before any planned conception attempt, allowing IGF-1 to return to baseline.

Lactation: Sermorelin has not been studied in breastfeeding women. Peptides are generally degraded in the infant GI tract and poorly absorbed, so systemic exposure in a nursing infant is likely to be minimal. However, GH-axis peptides could theoretically affect prolactin dynamics and milk supply. Given the absence of data and the availability of alternatives for managing long-COVID fatigue in breastfeeding women, sermorelin use during lactation is not recommended. Discuss this explicitly with your prescriber.

Fertility: If you are trying to conceive, sermorelin is not appropriate. Women with PCOS who are pursuing fertility treatment may have altered GH signaling, but GH or GH-secretagogue use in IVF is an area of active research and should be managed only by a reproductive endocrinologist, not through a general wellness protocol.

Who This Protocol Is Right For and Who Should Avoid It

Potentially Suitable

• Women with confirmed or probable long-COVID lasting more than 12 weeks, with documented fatigue, cognitive dysfunction, or post-exertional malaise
• Age-appropriate IGF-1 in the lower quartile or documented GH deficiency
• Perimenopausal or postmenopausal women whose long-COVID fatigue is layered on top of declining GH axis function
• Women who have not responded to standard long-COVID rehabilitation approaches and are under ongoing medical supervision
• Women with no contraindications listed below

Not Suitable or Requires Extra Caution

• Pregnant or trying to conceive
• Breastfeeding
• Active cancer or history of hormone-sensitive cancers (IGF-1 is a mitogen; this is not a theoretical concern)
• Uncontrolled diabetes or prediabetes with fasting glucose above 110 mg/dL
• Uncontrolled hypothyroidism (treat thyroid first; hypothyroidism will blunt any GH response)
• Women with PCOS and uncontrolled insulin resistance without metabolic optimization
• Active Cushing's syndrome or other conditions of cortisol excess
• Women on high-dose oral glucocorticoids (suppress GH secretion)

Interactions with Medications Common in Women with Long-COVID

Several medications frequently used in long-COVID management interact with the GH axis:

Low-dose naltrexone (LDN): Often used for long-COVID immune modulation. No known pharmacokinetic interaction with sermorelin, though both affect immune function through different pathways. Concurrent use is described in observational practice.

Oral estrogen (MHT or combined oral contraceptives): Increases GH clearance via hepatic first-pass metabolism, potentially reducing sermorelin effectiveness. Switching to transdermal estradiol delivery eliminates this interaction.

Thyroid hormone replacement: Women on levothyroxine should have thyroid levels optimized before starting sermorelin. GH can increase conversion of T4 to T3, potentially unmasking central hypothyroidism or altering levothyroxine requirements. Recheck TSH and free T4 at the 6-week monitoring visit.

Insulin and GLP-1 receptor agonists: GH antagonizes insulin action. Women on GLP-1 medications (semaglutide, tirzepatide) for COVID-related metabolic sequelae need closer glucose monitoring on sermorelin. GLP-1 agonists reduce appetite and body weight, while GH can transiently raise fasting glucose, creating a pharmacodynamic tension that requires monitoring rather than prohibition.

A Note on Compounding, Quality, and Regulatory Status

Sermorelin is available in the United States as a compounded peptide through licensed compounding pharmacies, typically as a lyophilized powder for reconstitution. The FDA does not approve compounded preparations; it oversees the pharmacies that produce them under 503A or 503B frameworks. Quality varies substantially between compounders.

When sourcing sermorelin:

• Use only a pharmacy registered with your state board of pharmacy and inspected under USP 797/800 standards
• Request a certificate of analysis (COA) from an independent third-party lab with each batch
• Confirm the peptide is stored refrigerated at 2-8 degrees Celsius after reconstitution
• Reconstituted sermorelin is generally stable for 30 days refrigerated

Peptides purchased from research-chemical suppliers without a prescription are not pharmaceutical-grade and carry unknown contamination and potency risks. This is a clinical tool requiring medical oversight, not a supplement.

What to Combine with Sermorelin in a Long-COVID Recovery Protocol

Sermorelin works best as part of a structured recovery program, not as a single intervention. The following adjuncts have the strongest evidence in long-COVID:

Sleep hygiene and circadian alignment: GH release is coupled to SWS. Without consistent sleep timing, sermorelin's bedtime mechanism is undermined. The NIH RECOVER sleep sub-study confirmed sleep disruption as a driver of long-COVID symptom persistence.

Graded exercise (carefully titrated): Post-exertional malaise requires pacing. Resistance training, even low-load, stimulates endogenous GH secretion and IGF-1. Start with 2 sessions per week at submaximal exertion and use heart-rate monitoring to stay below the anaerobic threshold.

Protein intake: IGF-1 synthesis requires adequate amino acid substrate. Target 1.2-1.6 g of protein per kg of body weight per day. Women in perimenopause and beyond have higher leucine thresholds for muscle protein synthesis and may need to prioritize leucine-rich proteins.

Thyroid optimization: As noted above, treat hypothyroidism first. Postpartum thyroiditis occurs in 5-10% of women within the first year after delivery and can present identically to long-COVID fatigue. Rule it out before attributing all symptoms to COVID sequelae.

Frequently Asked Questions